Monopar Therapeutics Files 2025 Proxy Statement
Ticker: MNPR · Form: DEF 14A · Filed: Apr 30, 2025 · CIK: 1645469
| Field | Detail |
|---|---|
| Company | Monopar Therapeutics (MNPR) |
| Form Type | DEF 14A |
| Filed Date | Apr 30, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, governance
Related Tickers: MNPR
TL;DR
Monopar Proxy filed. Vote on directors & auditors June 17.
AI Summary
Monopar Therapeutics Inc. filed its definitive proxy statement on April 30, 2025, for its annual meeting of stockholders scheduled for June 17, 2025. The filing details the company's corporate governance, executive compensation, and proposals to be voted on by shareholders. Key items likely include the election of directors and ratification of independent auditors.
Why It Matters
This filing provides shareholders with crucial information to make informed voting decisions on company leadership and important corporate matters, impacting the company's strategic direction.
Risk Assessment
Risk Level: low — This is a routine annual filing (DEF 14A) that outlines standard corporate governance and shareholder voting matters, not indicating new or unusual risks.
Key Players & Entities
- Monopar Therapeutics Inc. (company) — Registrant
- June 17, 2025 (date) — Annual Meeting Date
- April 30, 2025 (date) — Filing Date
FAQ
What is the purpose of this DEF 14A filing?
This filing is the definitive proxy statement for Monopar Therapeutics Inc., providing information to shareholders for their vote at the upcoming annual meeting.
When is Monopar Therapeutics' annual meeting of stockholders?
The annual meeting of stockholders is scheduled for June 17, 2025.
What is the filing date of this proxy statement?
The definitive proxy statement was filed on April 30, 2025.
What is the company's fiscal year end?
Monopar Therapeutics' fiscal year ends on December 31.
Where is Monopar Therapeutics headquartered?
Monopar Therapeutics is located at 1000 Skokie Blvd Suite 350, Wilmette, IL 60091.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 30, 2025 regarding Monopar Therapeutics (MNPR).